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1085Prognostic Value of RV Function Before and After
Lung TransplantationABSTRACTOBJECTIVES We investigated the effects of lung transplantation on right ventricular (RV) function as well asthe prognostic value of pre- and post-transplantation RV function.BACKGROUND Although lung transplantation success has improved over recent decades, outcomes remain achallenge. Identifying predictors of mortality in lung transplant recipients may lead to improved long-term
outcomes after lung transplantation.METHODS Eighty-nine (age 60  6 years, 58 men) consecutive patients who underwent single or double lung
transplantation and had pre- and post-transplantation echocardiograms between July 2001 and August 2012 were
evaluated. Echocardiographic measurements were performed before and after lung transplantation. Left ventricular (LV)
and RV longitudinal strains were analyzed using velocity vector imaging. Cox proportional prognostic hazard models
predicting all-cause death were built.RESULTS Therewere 46 all-cause (52%) and 17 cardiac (19%) deaths during 43 33months of follow-up. After
lung transplantation, echocardiography showed improved systolic pulmonary artery pressure (SPAP) (50 19mmHg to 40
 13 mm Hg) and RV strain (17  5% to 18  4%). No pre-transplantation RV parameter predicted all-cause mortality.
After adjustment for age, sex, surgery type, and etiology of lung disease in a Cox proportional hazards model, both post-
transplantation RV strain (hazard ratio: 1.13, 95% conﬁdence interval: 1.04 to 1.23, p ¼ 0.005), and post-transplantation
SPAP (hazard ratio: 1.03, 95% conﬁdence interval: 1.01 to 1.05, p ¼ 0.011) were independent predictors of all-cause
mortality. When post-transplantation RV strain and post-transplantation SPAP were added the clinical predictive model
based on age, sex, surgery type, and etiology, the C-statistic improves from 0.60 to 0.80 (p ¼ 0.002).CONCLUSIONS AlterationsofRV functionandpulmonary artery pressurenormalize, andpost-transplantationRVfunction may provide prognostic data in patients after lung transplantation. Our study is based on a highly and
retrospectively selected group. We believe that larger prospective studies are warranted to conﬁrm this result.
(J Am Coll Cardiol Img 2014;7:1084–94) © 2014 by the American College of Cardiology Foundation.SEE PAGE 1095L ung transplantation (LTx) is a treatment op-tion for patients with a range of end-stagelung pathologies. Although outcomes have
improved over the past several decades, at least in
part due to immunosuppressive medications, LTx
outcomes remain among the worst overall for organ
transplantation (1,2), Identifying predictors of mortal-
ity in lung transplant recipients is an important issue,
with the goal of improving long-term outcomes in
these patients. In a large cohort study, pulmonary hy-
pertension (PHT) before LTx has been shown to be a
prognostic factor in post-LTx survival in a univariate
analysis (3). The effects of advanced PHT on cardiac
anatomy and physiology are diverse, including right
ventricular (RV) dilation and hypertrophy, tricuspid
regurgitation (TR), and interventricular septum devi-
ation, with consequent impact on cardiac function
(4). Therefore, the evaluation of PHT in the absenceof knowledge of related cardiac changes, in particular
RV function, may be problematic. Recent work has
shown that direct measurement of RV function with
strain imaging (RV strain) is related to outcome in
valve disease and end-stage heart failure (5–7). In
addition, successful LTx may lead to normalization
of RV morphology and function, and the prognostic
value of RV morphology and function before and afterLTx has not been well characterized (8,9). We hypoth-
esized that LTx leads to normalization of both RV
strain and pulmonary artery pressure and that
improvement of both RV strain and pulmonary artery
pressure (PAP) would result in a good outcome. In
this study, we investigated the effects of LTx on RV
function as well as the prognostic value of pre- and
post-transplantation RV function.
ABBR EV I A T I ON S
AND ACRONYMS
CI = conﬁdence interval
HR = hazard ratio
LA = left atrial
LTx = lung transplantation
LV = left ventricular
PAP = pulmonary artery
pressure
PHT = pulmonary hypertension
PVR = pulmonary vascular
resistance
RV = right ventricular
RVEDA = right ventricular
end-diastolic area
RVFAC = right ventricular
fractional area change
SPAP = systolic pulmonary
artery pressure
TR = tricuspid regurgitation
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1086METHODS
STUDY POPULATION. This was a retrospec-
tive observational cohort study. Between
July 2001 and August 2012, a total of 933 pa-
tients underwent primary LTx for end-stage
lung disease at our institution. Although
there is standardized clinical follow-up for
all patients after LTx, echocardiography is
obtained only in those patients with cardiac
history or a clinical indication. Therefore, we
identiﬁed 95 consecutive patients who had
an echocardiogram at baseline (within 3
months before LTx) and at follow-up (at least
3 months after LTx) for inclusion in the
study. Six patients were excluded because of
poor image quality and low frame rate
deﬁned as <40 frame/s. Therefore, 89 pa-
tients were included for the ﬁnal analysis.
Based on an assumed rate of death of w60%
during a follow-up period, we anticipated 83patients would be needed to develop a stable statis-
tical model with 5 variables (10). Given the retro-
spective nature of the study, the Cleveland Clinic
Institutional Review Board approved waiver of pa-
tient consent because we minimized risk by de-
identifying protected health data. Recipient and
surgery data were extracted from the Uniﬁed Trans-
plant Database. Also, a supplemental review of med-
ical records was performed.
CLINICAL OUTCOMES. All-cause mortality was the
primary endpoint. Death notiﬁcation was conﬁrmed
by observation of a death certiﬁcate or veriﬁed by a
family member. The duration of follow-up was star-
ted at the time of the follow-up echocardiogram and
ended in June 2013. The secondary endpoint was
cardiovascular death. Cardiovascular death included
death due to heart failure and sudden cardiac death
(including sudden death at home).
LEFT VENTRICULAR FUNCTION. All patients under-
went comprehensive echocardiography performed by
dedicated cardiac sonographers with commercially
available instruments (Philips Medical Systems, NA,
Bothell, Washington; General Electric Medical Sys-
tems, Milwaukee, Wisconsin; and Siemens Medical
Solutions USA, Inc., Malvern, Pennsylvania) as part of
a standard clinical diagnostic evaluation before and
after LTx. Measurements and recordings were ob-
tained according to the American Society of Echo-
cardiography recommendations (11). Left ventricular
(LV) end-diastolic volume, LV end-systolic volume,
and left atrial (LA) volume were calculated by the
Simpson method using 2-dimensional images andindexed to body surface area. Stroke volume was
calculated as the product of the cross-sectional area
of the LV outﬂow tract and the time-velocity integral
in the LV outﬂow tract. The transmitral early diastolic
velocity (E) and peak atrial ﬁlling velocity (A) were
acquired in the apical 4-chamber view. The early dia-
stolic (e0) mitral annular tissue velocity was also
measured in the apical 4-chamber view with the sam-
ple volume positioned at both the septal and lateral
mitral annuli; we used the average values of these 2
positions. LV peak longitudinal strain measurements
were obtained from gray-scale images recorded in the
apical 4-chamber, 2-chamber, and long-axis views.
The frame rate was maintained at a level >40 and <80
frame/s. LV strain was analyzed ofﬂine using velocity
vector imaging (Syngo VVI, Siemens Medical Solu-
tions, Mountain View, California) (6). Good image
quality was deﬁned as clear detection of the endocar-
dial border throughout the cardiac cycle, and regions
of interest at the apex and annulus were ensured. After
manual deﬁnition of the LV endocardial border, the
endocardium was automatically tracked throughout
the cardiac cycle. Global LV strain was obtained
by averaging all segmental strain values from the api-
cal 4-chamber, 2-chamber, and long-axis views.
RV FUNCTION. Standard echocardiographic measure-
ments of the right ventricle weremade in accordance with
current guidelines (12). Right ventricular fractional
area change (RVFAC) was deﬁned using the formula: (end-
diastolic area end-systolic area)/end-diastolic area 100.
Tricuspid annular plane systolic excursion was measured
as the distance of systolic movement of the anterior tri-
cuspid annulus toward the RV apex using 2-dimensional
images. Systolic pulmonary artery pressure (SPAP) was
estimated from the maximal continuous-wave Doppler
velocity of the TR jet using systolic transtricuspid pressure
gradient calculated by themodiﬁedBernoulli equationand
the addition of estimated right atrial pressure as previously
described (13). An index of pulmonary vascular resistance
(PVR) was derived by dividing the maximal velocity of the
TR jet by the RV outﬂow tract time-velocity integral. RV
strainwasmeasuredofﬂine (SyngoVVI) (6). Likewise, good
image quality in RV assessment was deﬁned as clear
detection of the endocardial border throughout the cardiac
cycle. The endocardial border of theRVwas traced from an
apical 4-chamber view, and segmental strain curves were
generated automatically. Peak strain for the 3 RV free wall
segments was averaged to produce global RV longitudinal
strain, with exclusion of the interventricular septum to
avoid LV interaction (6,7,14) (Figure 1, Online Video 1,
Online Figure 1). All measurements were made ofﬂine by
an investigator blinded to all clinical and demographic
information and were performed and averaged over 3
cardiac cycles.
FIGURE 1 Images Before and After Lung Transplantation
Before lung transplantation, right ventricular fractional area change (RVFAC) and right ventricular (RV) strain were depressed and tricuspid
valve regurgitation velocity (TR-V) was accelerated. After lung transplantation, these variables improved. Online Video 1 shows the RV strain
curve from a post-operative echocardiogram.
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1087PULMONARY PATHOLOGY. The pathological analysis
of all explanted lungs was reviewed to categorize
lung pathology in all cases according to guidelines.
The pulmonary ﬁbrosis disease group was identiﬁed
by usual interstitial pneumonia in pathology (15). The
chronic obstructive pulmonary disease group was
identiﬁed by emphysema in pathology (16).
STATISTICAL ANALYSIS. Data are presented as
mean  SD if the Kolmogorov-Smirnov test showed
a normal distribution. Otherwise, the median and
interquartile ranges were used. Comparisons between
before and after LTx data were performed by paired
Student t test. Median values of RV strain (pre: 16%
and post: 18%) and SPAP (pre: 47 mm Hg and post:
39 mm Hg) were used to divide patients into 2 equal
groups for Kaplan-Meier analysis, with survival
compared using a 2-sided log-rank test. The associa-
tion of echocardiographic parameters with outcomewas identiﬁed by Cox proportional hazards models
in univariable and multivariable analyses. Variables
with a univariable value of p < 0.10 after adjustment
for age and sex were incorporated into the multi-
variable models. In addition, surgery type (single or
double LTx) and etiology (idiopathic pulmonary
ﬁbrosis or not) were incorporated into the ﬁnal model
because this factor is a marker for a high-risk group of
patients (17). To avoid collinearity in situations in
which >1 variable measured the same physiological
parameter (e.g., RVFAC and RV strain as markers of
RV systolic function), separate models were created
for each categorical variable (LV variables and RV
variables). A hazard ratio (HR) with a 95% conﬁdence
interval (CI) was calculated for each variable. The
assumption of proportional hazards was assessed by
plotting the scaled Schoenfeld residuals for each in-
dependent variable against time; these correlations
TABLE 2 Baseline (Pre) and After Transplantation (Post)
Echocardiography Data
LV Function Pre Post p Value
LVEDV, ml 84  26 95  30 0.001
LVESV, ml 34  14 37  16 0.017
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1088were found to be nonsigniﬁcant. We performed
analysis stratiﬁed by echocardiographic variables for
interaction and found no evidence of interaction in
our ﬁnal model. Sequential Cox models were per-
formed to determine the incremental prognostic
beneﬁt of echocardiographic parameters over clinical
data, with an incremental prognostic value being
deﬁned by a signiﬁcant increase in global chi-square.
Net reclassiﬁcation index was evaluated to assess
the incremental beneﬁt of adding post–RV strain and
post-transplantation SPAP to the baseline model
(age, sex, surgery type, and etiology). To evaluate the
predictive ability of our model, we used Harrell’s C
concordance statistic calculated. The method of
DeLong was used to study differences in C-index (18).
Receiver-operating characteristic curves were gener-
ated to determine optimal cutoff values of continuous
variables. The best cutoff value was deﬁned as the
upper limit of the CI of the Youden index. To validate
SPAP estimation by echocardiography, we used data
from 35 patients from our series of 95 patients who
also had a right heart catheterization performed
within 7 days to assess PAP. RV strain for each patient
was performed in a blinded manner by 3 independent
observers. Each observer performed 2 independent
measurements of RV strain values on the same
echocardiographic images in a randomly selected
group of 9 patients (3 patients with excellent image
quality, 3 patients with good image quality, and 3
patients with poor image quality). Variability wasTABLE 1 Baseline Clinical Variables (N ¼ 89)
Age, yrs 61  6
Male 58 (65)
Body surface area, m2 1.9  0.2
Heart rate, beats/min 79  13
Systolic blood pressure, mm Hg 127  16
Diastolic blood pressure, mm Hg 71  9
Diagnosis
COPD (emphysema) 41 (46)
Pulmonary ﬁbrosis (usual interstitial pneumonia) 48 (54)
Comorbidities
Hypertension 38 (43)
Coronary artery disease 17 (19)
Diabetes mellitus 24 (27)
Surgery
Single-lung transplantation 49 (55)
Invasive hemodynamic data
Right atrial pressure, mm Hg 7  4
Pulmonary capillary wedge pressure, mm Hg 12  7
Systolic pulmonary artery pressure, mm Hg 48  13
Cardiac output (Fick), l/min 5  2
Values are mean  SD or n (%).
COPD ¼ chronic pulmonary obstructive disease.tested with 2-way analysis of variance with calcula-
tion of intraobserver and interobserver standard
error of the mean (SEMintra and SEMinter).
SEMintra expresses the random error by a single
observer, whereas SEMinter is an indicator of the mean
variation between different observers. Statistical
analysis was performed using standard statistical
software packages (SPSS version 20.0, SPSS Inc.,
Chicago, Illinois and R software version 2.12.0, R
Project, Vienna, Austria), and statistical signiﬁcance
was deﬁned as p < 0.05.
RESULTS
STUDY POPULATION. Baseline clinical and hemody-
namic variables are shown in Table 1. The mean age of
the 31 female and 58 male patients was 61 years. All
patients were in New York Heart Association func-
tional class III or IV. Pathological analysis revealed
that there were 48 pulmonary ﬁbrosis patients (54%)
and 41 patients (46%) with chronic obstructive pul-
monary disease. There were 49 (55%) single LTx pa-
tients and 41 (45%) double LTx patients. There were
comorbidities in this group, mainly patients with
hypertension (43%).LVSV, ml 50  16 58  18 <0.001
LVEF, % 60  7 61  7 0.129
LAVi, ml 43  17 54  19 <0.001
E/A ratio 0.9  0.3 1.2  0.7 <0.001
E/e0 ratio 8.8  3.2 10.2  3.6 0.007
RV function
RVEDA, cm2 22  7 20  5 0.016
RVESA, cm2 13  5 11  3 <0.001
RVFAC, % 40  6 43  6 <0.001
RA area, cm2 14  4 15  4 0.047
TAPSE, cm 1.8  0.3 1.9  0.4 0.123
SPAP, mm Hg 50  19 40  13 <0.001
PVR, Wood units 2.3  0.9 1.8  0.5 <0.001
IVC, cm 1.5  0.4 1.6  0.4 0.138
Strain, %
LV 16  3 16  3 0.158
RV 17  5 19  4 0.011
Values are mean  SD. Bold indicates p # 0.05.
A-wave ¼ transmitral atrial ﬁlling wave; e0 velocity ¼ early diastolic mitral
annular tissue velocity; E-wave ¼ transmitral early diastolic wave; IVC ¼ inferior
vena cava; LAVi ¼ left atrial volume index; LV ¼ left ventricular; LVEDV ¼ left
ventricular end-diastolic volume; LVEF ¼ left ventricular ejection fraction;
LVESV ¼ left ventricular end-systolic volume; LVSV ¼ left ventricular systolic
volume; PVR ¼ pulmonary vascular resistance; RA ¼ right atrial; RV ¼ right ven-
tricular; RVEDA ¼ right ventricular end-diastolic area; RVESA ¼ right ventricular
end-systolic area; RVFAC ¼ right ventricular fractional area change; SPAP ¼ sys-
tolic pulmonary artery pressure; TAPSE ¼ tricuspid annular plane systolic
excursion.
TABLE 3 Baseline (Pre) and After Transplantation (Post) in Echocardiography,
Stratiﬁed by Etiology and Pulmonary Hypertension
Pre Post p Value Pre Post p Value
COPD (Emphysema) Pulmonary Fibrosis
LVEDV, ml 83  27 100  25 <0.001 85  26 90  34 0.148
LVESV, ml 33  14 40  15 0.006 34  14 34  17 0.426
LVSV, ml 50  17 60  15 0.001 50  15 57  20 0.028
LVEF, % 61  8 60  8 0.289 60  7 63  7 0.007
LAVi, ml 37  16 56  18 <0.001 48  16 53  20 0.053
E/A ratio 1.0  0.4 1.3  0.9 0.016 1.0  0.4 1.1  0.4 0.003
E/e0 ratio 8.4  2.9 10.4  4.0 0.018 9.0  3.3 10.0  3.2 0.044
RVEDA, cm2 19  7 20  5 0.339 23  6 20  4 <0.001
RVESA, cm2 12  6 11  4 0.299 14  4 11  2 <0.001
RVFAC, % 40  6 43  6 0.012 39  6 43  5 <0.001
SPAP, mm Hg 47  16 39  11 0.002 52  20 42  14 <0.001
PVR, Wood units 2.2  0.9 1.8  0.6 0.003 2.4  0.9 1.8  0.5 <0.001
LV strain, % 15  3 15  3 0.422 16  3 17  3 0.105
RV strain, % 17  3 18  4 0.224 16  4 18  4 0.007
High SPAP
(>Median Value of SPAP)
Low SPAP
(#Median Value of SPAP)
LVEDV, ml 80  21 94  28 0.002 87  30 95  33 0.074
LVESV, ml 32  12 36  33 0.069 35  16 38  18 0.138
LVSV, ml 48  13 57  18 <0.001 52  18 58  18 0.049
LVEF, % 60  8 61  8 0.185 62  7 61  7 0.249
LAVi, ml 40  16 52  19 <0.001 45  18 56  20 <0.001
E/A ratio 0.9  0.3 1.1  0.6 <0.001 0.9  0.4 1.2  0.8 0.013
E/e0 ratio 8.3  2.4 10.4  4.4 0.003 9.2  3.2 10.0  2.8 0.119
RVEDA, cm2 19  6 19  4 0.445 23  7 20  5 0.006
RVESA, cm2 11  4 11  3 0.278 15  7 12  3 <0.001
RVFAC, % 42  5 43  5 0.101 38  7 43  7 <0.001
SPAP, mm Hg 36  7 38  11 0.107 63  17 43  14 <0.001
PVR, Wood units 1.8  0.6 1.7  0.4 0.288 2.7  0.9 1.8  0.5 <0.001
LV strain, % 15  3 16  3 0.136 16  3 16  3 0.367
RV strain, % 17  5 18  4 0.308 16  4 18  4 0.006
Values are mean  SD. Bold indicates p value #0.05.
Abbreviations as in Tables 1 and 2.
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1089EFFECT OF LTX ON CARDIAC FUNCTION. The me-
dian time from preoperative echocardiography to
surgery was 1 month (range 0 to 3 months). The
median time to follow-up echocardiography was 11
months (range 3 to 60 months). Echocardiographic
variables before and after LTx are shown in Table 2.
There were no signiﬁcant differences in LV ejection
fraction, right atrial area, tricuspid annular plane
systolic excursion, inferior vena cava, and LV strain
before and after LTx (all p > 0.05), whereas LV end-
diastolic volume (p ¼ 0.007), LV stroke volume
(p ¼ 0.006), and LA volume (p < 0.001) signiﬁcantly
increased after LTx. E/A ratio (p ¼ 0.001) and E/e0
(p ¼ 0.007) ratio also increased after LTx. For the
RV functional variables, the RV areas (p ¼ 0.033 and
p < 0.001), SPAP (p < 0.001), and PVR (p < 0.001)
signiﬁcantly decreased, whereas RVFAC (p < 0.001)
and RV strain improved (p ¼ 0.021). Echocardio-
graphic characteristics stratiﬁed by etiology
and high PAP are shown in Table 3. In both the
chronic obstructive pulmonary disease and pulmo-
nary ﬁbrosis groups, LTx led to improvement in RV
systolic function (RVFAC) and a concomitant in-
crease in LV stroke volume and LV pre-load
(quantiﬁed as LA volume). Interestingly, the patients’
pre-transplantation SPAP inﬂuenced the post-
transplantation improvement of RV function
(Table 3). Especially in higher PAP before trans-
plantation, LTx led to diminished right atrial and RV
size, and improvement in RV systolic function
(RVFAC and RV strain) and hemodynamic parameters
(SPAP and PVR).
EVENT-FREE SURVIVAL. Over a period of 43  33
months (range 5 to 137 months), 46 (52%) patients
reached the primary endpoint (all-cause death) and
17 (19%) patients reached the secondary endpoint
(cardiovascular death). The causes of death were
sepsis/multisystem organ failure (n ¼ 14, 30%),
respiratory infection (n ¼ 9, 19%), chronic rejection
(n ¼ 5, 11%), malignancy (n ¼ 1, 2%), heart failure
(n ¼ 12, 26%), and sudden cardiac death (n ¼ 5,
10%). Figure 2 illustrates the event-free survival
of patients after LTx stratiﬁed according to median
values of RV strain and SPAP. Patients with
RV abnormality (RV strain $18% [median value])
and PAP abnormality (SPAP $39 mm Hg [median
value]) had signiﬁcantly shorter event-free survival
than those without these abnormalities; the 3-year
event-free survival rates in patients without post-
transplantation RV abnormality or PAP abnormality
and in patients with post-transplantation RV and
PAP abnormalities were 73% and 36%, respectively
(p < 0.001).PREDICTING EVENT-FREE SURVIVAL. E/e0 at base-
line, RV end-diastolic area (RVEDA), SPAP, LV strain,
and RV strain after LTx were associated with all-
cause death, independent of age and sex. In addi-
tion, LA volume, E/e0 and RVEDA at baseline, and
SPAP, PVR and RV strain after LTx were also associ-
ated with cardiac death, independent of age and
sex (Table 4). Interestingly, there were no pre-
transplantation RV parameters to predict all-cause
mortality. In multivariable Cox proportional hazards
models, LV strain at baseline (HR: 1.23, 95% CI: 1.00 to
1.52, p ¼ 0.05, model 1), SPAP after LTx (HR: 1.03, 95%
CI: 1.01 to 1.05, p ¼ 0.011, model 2), and RV strain after
LTx (HR: 1.13, 95% CI: 1.04 to 1.23, p ¼ 0.005, model 2)
were independently associated with all-cause death.
Even after adjustment for the time interval of post-
LTx, the results remained the same (SPAP after LTx,
FIGURE 2 Kaplan-Meier Analysis of Event-Free Survival After Lung Transplantation
Patients were stratiﬁed according to high pulmonary artery pressure (PH) and right ventricular abnormality. PAP ¼ pulmonary artery pressure;
RV ¼ right ventricular; RVD ¼ right ventricular dysfunction.
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1090HR: 1.03, 95% CI: 1.01 to 1.06, p ¼ 0.023, model 3;
RV strain after LTx, HR: 1.16, 95% CI: 1.07 to 1.26,
p ¼ 0.001, model 3) (Table 5). The incremental beneﬁt
of echocardiographic parameters in the prediction of
events is shown in Figure 3. The addition of echo-
cardiographic parameters signiﬁcantly improved the
prognostic power of a model containing clinical var-
iables (model 1: age, sex, surgery type, and etiology,
chi-square ¼ 1.6; model 2: plus LV strain as an LV
function, chi-square ¼ 8.4, p ¼ 0.011; model 3: plus
SPAP as an RV afterload parameter, chi-square ¼ 16.8,
p ¼ 0.010; model 4: plus RV strain as an RV function,
chi-square ¼ 24.0, p ¼ 0.011). The combination of
post-transplantation RV strain þ post-transplantation
SPAP with the baseline model (age, sex, surgery type,
and etiology) led to a signiﬁcant reclassiﬁcation
improvement (net reclassiﬁcation index: 0.53 [0.22 to
0.84], p < 0.001). Furthermore, for our Cox model
based on age, sex, surgery type, and etiology, the
Harrell C concordance statistic was calculated to be
0.60. When post-transplantation RV strain and post-
transplantation SPAP are added to the models, the
C-statistic improves to 0.80 (p ¼ 0.002). The area
under the receiver-operating characteristic curve
was used to designate the best cutoff valuesto predict the occurrence of events, namely,
post-transplantation SPAP >45 mm Hg (area under
the receiver-operating characteristic curve 0.65,
p ¼ 0.01), and post-transplantation RV strain >17%
(area under the receiver-operating characteristic
curve: 0.77, p < 0.001).
ACCURACY AND VARIABILITY FOR ECHOCARDIO-
GRAPHIC PARAMETERS. There was a good correla-
tion between SPAP obtained by echocardiography
and right heart catheterization (r ¼ 0.86, p < 0.001)
(Online Figure 2), similar to the ﬁnding of recent in-
vestigators (19). In the excellent image quality group,
SEMintra was 0.9% and SEMinter was 1.2%. In the good
image quality group, SEMintra was 1.1% and SEMinter
was 1.4%. Finally, in the poor image quality group,
SEMintra was 2.8% and SEMinter was 3.9%. We
included only excellent and good image quality data
in the ﬁnal cohort.
DISCUSSION
After LTx, increased LV and LA size was noted, as was
increased LV ﬁlling pressure (E/A and E/e0 ratios),
alteration of RV size (RVEDA and RV end-systolic
area), function (RVFAC and RV strain), and
TABLE 4 Univariable Associations of All-Cause Death
and Cardiac Death
All-Cause Death Cardiac Death
Adjustment for
Age and Sex
Adjustment for
Age and Sex
HR (95% CI) p Value HR (95% CI) p Value
Baseline
LVEDV 1.01 (0.99–1.02) 0.55 1.01 (0.99–1.03) 0.31
LVSV 1.01 (0.99–1.03) 0.35 1.02 (0.98–1.06) 0.18
LVEF 1.03 (0.98–1.07) 0.23 1.04 (0.97–1.12) 0.27
LAVi 1.01 (0.99–1.03) 0.37 1.03 (1.00–1.06) 0.03
E/A 0.92 (0.36–2.35) 0.86 2.51 (0.80–7.86) 0.11
E/e0 1.15 (1.00–1.33) 0.05 1.32 (1.09–1.59) 0.003
RVEDA 1.02 (0.98–1.06) 0.46 1.07 (1.01–1.14) 0.02
RVESA 1.01 (0.96–1.07) 0.73 1.08 (0.99–1.17) 0.06
RVFAC 1.01 (0.97–1.06) 0.67 0.99 (0.93–1.07) 0.84
SPAP 0.99 (0.98–1.01) 0.32 1.00 (0.98–1.03) 0.92
PVR 0.94 (0.65–1.35) 0.73 1.08 (0.63–1.84) 0.78
LV strain 1.01 (0.91–1.12) 0.85 1.03 (0.88–1.21) 0.85
RV strain 0.96 (0.89–1.02) 0.16 1.05 (0.94–1.18) 0.38
After transplantation
LVEDV 1.00 (0.98–1.07) 0.47 1.00 (0.93–1.08) 0.15
LVSV 1.00 (0.97–1.02) 0.49 0.99 (0.94–1.00) 0.07
LVEF 1.00 (0.97–1.04) 0.85 0.98 (0.93–1.05) 0.62
LA volume 1.00 (0.98–1.02) 0.61 1.00 (0.96–1.03) 0.46
E/A 0.94 (0.61–1.43) 0.76 0.93 (0.48–1.80) 0.83
E/e0 1.09 (0.98–1.20) 0.11 1.05 (0.89–1.24) 0.11
RVEDA 1.07 (1.00–1.14) 0.05 1.04 (0.93–1.17) 0.47
RVESA 1.01 (0.99–1.21) 0.07 1.06 (0.90–1.25) 0.51
RVFAC 0.99 (0.94–1.05) 0.71 1.00 (0.91–1.08) 0.89
SPAP 1.04 (1.02–1.06) <0.001 1.05 (1.02–1.09) 0.004
PVR 1.76 (0.99–3.14) 0.06 2.56 (1.08–6.15) 0.03
LV strain 1.13 (1.02–1.25) 0.017 1.11 (0.94–1.32) 0.22
RV strain 1.15 (1.06–1.26) 0.001 1.24 (1.06–1.46) 0.01
The hazard ratio for a 1-U increase in the predictor (e.g., ml, %, and mm Hg).
Bold indicates p # 0.05.
CI ¼ conﬁdence interval; HR ¼ hazard ratio; other abbreviations as in Table 2.
TABLE 5 Cox Proportional-Hazards Regression Analysis for
the Prediction of All-Cause Death in Multivariate Model
HR (95% CI) p Value
Model 1 with LV variables Chi-square ¼ 10.2
Age 0.97 (0.89–1.05) 0.45
Male 0.57 (0.21–1.58) 0.28
Double transplantation 1.31 (0.43–4.00) 0.64
Pulmonary ﬁbrosis 1.45 (0.47–4.47) 0.52
E/e0 at baseline 1.16 (0.99–1.35) 0.07
LV strain after transplantation 1.23 (1.00–1.52) 0.05
Model 2 with RV variables Chi-square ¼ 23.8
Age 1.03 (0.98–1.08) 0.21
Male 1.15 (0.59–2.23) 0.68
Double transplantation 1.43 (0.75–2.77) 0.29
Pulmonary ﬁbrosis 0.93 (0.50–1.71) 0.80
SPAP after transplantation 1.03 (1.01–1.05) 0.011
RV strain after transplantation 1.13 (1.04–1.23) 0.005
Model 3 after adjustment of time
interval of post-Tx
Chi-square ¼ 25.7
Age 1.02 (0.96–1.07) 0.59
Male 1.26 (0.65–2.44) 0.49
Double transplantation 0.89 (0.45–1.77) 0.73
Pulmonary ﬁbrosis 0.92 (0.49–1.72) 0.79
Time interval after surgery
(per month)
0.99 (0.97–1.01) 0.31
SPAP after transplantation 1.03 (1.01–1.06) 0.023
RV strain after transplantation 1.16 (1.07–1.26) 0.001
The hazard ratio for a 1-U increase in the predictor (e.g., ml, %, and mm Hg).
Bold indicates p # 0.05.
Tx ¼ transplant; other abbreviations as in Tables 2 and 4.
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1091improvement of PHT (SPAP). Post-LTx impaired RV
strain and increased SPAP were independent pre-
dictors of all-cause death. Post-transplantation RV
function may provide important prognostic data in
patients with LTx. Pre-transplantation RV parame-
ters, however, did not predict outcome, suggesting
that increased SPAP and reduced RV function may not
discourage clinicians from considering LTx. However,
our study is based on a highly and retrospectively
selected group, as these patients were selected as
suitable candidates for transplantation and also sur-
vived to undergo post-transplantation echocardiog-
raphy; therefore, larger prospective studies are
needed to verify the beneﬁt of pre- and post-
transplantation RV function in this cohort.
CARDIAC FUNCTION IN LTX. Severe pulmonary dis-
ease affects the right and left ventricles, pulmonaryvascular bed, and venous return. It also leads to
increased expiratory pressures in the thoracic cavity
and to a decrease in stroke volume and cardiac output
(20). In our study, post-LTx echocardiographic ex-
aminations showed that stroke volume increased and
RV size, function, and SPAP normalized, which
resulted in a reverse remodeling of the distorted
cardiac geometry, especially in higher PAP before
transplantation. In addition, RV strain as a sensitive
marker of RV function also improved after LTx.
Although the etiology of these changes is likely
multifactorial, one likely contributing factor is
diminished PAP (RV afterload), with associated
normalization of RV size and function. These results
are consistent with those of previous work that
showed normalization of SPAP and RV geometry after
LTx (8,9). Interestingly, E/A and E/e0, markers of LV
ﬁlling pressure, increased after LTx. The cause of LV
dysfunction in pulmonary disease is not fully under-
stood given the complex interaction between cardiac
and pulmonary physiology (21). One possible expla-
nation is that venous return normalized after LTx and
led to increased LV pre-load in a setting of pre-clinical
LV dysfunction.
FIGURE 3 Incremental Prognostic Value of Echocardiographic Parameters When Added to Clinical Data
Illustration of the change in global chi-square of sequential Cox models incorporating clinical (age, sex, surgery type, and lung disease
etiology), left ventricular (LV) function (global LV strain), pulmonary hypertension (systolic pulmonary artery pressure [SPAP]), and right
ventricular (RV) function (RV strain).
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1092PREDICTORS OF MORTALITY IN LTX. There is
increasing recognition of the prognostic information
provided by RV function in cardiovascular disorders
such as heart failure and PHT (22). Moreover, quan-
titative measurement of RV size and function is
important in the prediction of clinical outcomes in
several disease states (6,14). In LTx patients, pre-LTx
SPAP has also been shown to be associated with
mortality, based on an analysis from the registry
of the International Society for Heart and Lung
Transplantation. However, there was no association
between pre-LTx SPAP and clinical outcome shown
on multivariable analysis (3). In listing the criteria of
LTx, pre-LTx increased SPAP was not included (23).
Our ﬁndings are consistent with those of previously
published work. In addition, pre-LTx RV echocar-
diographic parameters are strongly inﬂuenced by
the afterload status (lung status) (24). As shown in
our results, RV parameters improved after LTx and
may provide a valuable tool to assess prognosis. We
also evaluated the contribution of RV systolicfunction and SPAP. Especially in the post-LTx pop-
ulation, many echocardiographic RV parameters
were found to be within normal range. This suggests
that more sensitive markers are required to detect
subclinical RV dysfunction. Several investigators
have suggested that RV strain can detect cardiac
dysfunction earlier than standard imaging parame-
ters and is associated with clinical outcomes (6,7,14).
Our ﬁndings support the advantage of RV strain in
the early detection of RV dysfunction. Therefore, the
combination of impaired RV strain and increased
SPAP may provide incremental predictive value for
the prognosis of LTx patients. Previous studies also
suggested that several clinical features were associ-
ated with mortality after LTx. Our institution has
shown that survival is worse after LTx for idiopathic
pulmonary ﬁbrosis and when single LTx is performed
than for other clinical scenarios of LTx (17). There-
fore, we incorporated the etiology of pre-existing
disease and the type of surgery performed into the
ﬁnal model. However, in the present study, neither
J A C C : C A R D I O V A S C U L A R I M A G I N G , V O L . 7 , N O . 1 1 , 2 0 1 4 Kusunose et al.
N O V E M B E R 2 0 1 4 : 1 0 8 4 – 9 4 RV Function With Lung Transplantation
1093of these factors was signiﬁcantly associated with
mortality after LTx. A possible explanation for this is
the relatively small sample size in the current
investigation. Therefore, our ﬁndings may not be
extrapolated to all patients after LTx.
STUDY LIMITATIONS. This was a single-center study
that included a select population of LTx patients
including only those with follow-up echocardio-
graphic studies and was not a prospective study.
Further prospective study with a large study
population is required to elucidate that post-
transplantation RV function can risk-stratify pa-
tients after LTx. In addition, we could not enter
some pertinent clinical variables (for example,
donor status) due to the relatively small sample
size, which poses a potential risk of model overﬁt.
With the cardiac death model, there is the potential
of over ﬁtting due to censoring of the cases with
noncardiac death (25). The present study should be
considered as hypothesis generating, and we believe
that larger multicenter studies are warranted.
Moreover, there was considerable variation in the
time to post-operative echocardiography in this
study, and this may have affected our ability to
detect improvement in subclinical cardiac dysfunc-
tion after LTx. Additionally, because post-LTx pa-
tients only undergo echocardiography in the setting
of cardiac history or clinical indication, referral bias
may be present in our study. Echocardiographic
variables may be late features associated with clin-
ical decline rather than an early predictor of futuredecline. Velocity vector imaging is vendor-
independent strain software that is relatively easy
to use, but its clinical utility remains unproven. We
were not able to assess the strain rate using strain
imaging due to the limited frame rate (26).
CONCLUSIONS
In post-LTx patients, impaired RV strain and in-
creased SPAP were independently associated with all-
cause mortality. Alterations of RV function and PAP
normalize, and post-transplantation RV function may
provide important prognostic data in LTx patients.
Incorporating more detailed evaluation of the effects
of PHT on cardiac anatomy and function may improve
prediction models of outcome in this challenging
patient group. Interestingly, pre-transplantation RV
parameters did not predict outcome, suggesting
that increased SPAP and reduced RV function may
not discourage clinicians from considering LTx.
Our study is based on a highly and retrospectively
selected group. We believe that larger prospective
studies are warranted to conﬁrm this result.
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